Stimulating brain recovery after stroke using theranostic albumin nanocarriers loaded with nerve growth factor in combination therapy

Feczkó, Tivadar; Piiper, Albrecht; Ansar, Saema; Blixt, Frank W; Ashtikar, Mukul; Schiffmann, Susanne; Ulshöfer, Thomas; Parnham, Michael J.; Harel, Yifat; Israel, L.; Lellouche, Jean Paul; Wacker, Matthias G.

doi:10.1016/j.jconrel.2018.11.017

Cited by 32 publications

(25 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The transport of NGF was investigated using a Transwell system and bEnd3 cells, and ApoE‐functionalized HSA NPs caused significantly higher NGF levels in the basolateral compartment. [ 77 ]…”

Section: Drug Formulationmentioning

confidence: 99%

From Adsorption to Covalent Bonding: Apolipoprotein E Functionalization of Polymeric Nanoparticles for Drug Delivery Across the Blood–Brain Barrier

Hartl

Adams

Merkel

2020

Advanced Therapeutics

View full text Add to dashboard Cite

The blood–brain barrier (BBB) is composed of brain endothelial cells, pericytes, and astrocytes, which build a tight cellular barrier. Therapeutic (macro)molecules are not able to transit through the BBB in their free form. This limitation is bypassed by apolipoprotein E (ApoE)‐functionalized polymeric nanoparticles (NPs) that are able to transport drugs (e.g., dalargin, loperamide, doxorubicin, and nerve growth factor) across the BBB via low density lipoprotein (LDL) receptor‐mediated transcytosis. Coating with polysorbate 80 or poloxamer 188 facilitates ApoE adsorption onto polymeric NPs enabling recognition by LDL receptors of brain endothelial cells. This effect is even enhanced when NPs are directly coated with ApoE without surfactant anchor. Similarly, covalent coupling of ApoE to NPs that bear reactive groups on their surface leads to significantly improved brain uptake while avoiding the use of surfactants. In this Progress Report several in vitro BBB models using brain endothelial cells or cocultures with astrocytes/pericytes/glioma cells are described, which provide insights regarding the ability of a drug delivery system to cross this barrier. In vivo models are described which simulate central nervous system‐relevant diseases such as Alzheimer's or Parkinson's disease and cerebral cancer.

show abstract

Section: Drug Formulationmentioning

confidence: 99%

From Adsorption to Covalent Bonding: Apolipoprotein E Functionalization of Polymeric Nanoparticles for Drug Delivery Across the Blood–Brain Barrier

Hartl

Adams

Merkel

2020

Advanced Therapeutics

View full text Add to dashboard Cite

show abstract

“…[62][63][64][65][66][67][68] An alternative strategy involves ligands to bind receptors and alter intracellular signalling, such as the channel blockers, MRZ2/576 and riluzole, as well as the neuropeptide, nerve growth factor (NGF). [69][70][71] Another unique strategy is to deliver nucleic acids to modulate gene expression instead, such as miR-195, C3 siRNA and other plasmid vectors. [72][73][74] Free radicals had also been used as ROS scavengers among different treatment approaches to reduce I/R injury.…”

Section: Polymer-based Carriers Micellesmentioning

confidence: 99%

<p>Nanocarriers for Stroke Therapy: Advances and Obstacles in Translating Animal Studies</p>

Alkaff¹,

Radhakrishnan²,

Nedumaran³

et al. 2020

IJN

View full text Add to dashboard Cite

The technology of drug delivery systems (DDS) has expanded into many applications, such as for treating neurological disorders. Nanoparticle DDS offer a unique strategy for targeted transport and improved outcomes of therapeutics. Stroke is likely to benefit from the emergence of this technology though clinical breakthroughs are yet to manifest. This review explores the recent advances in this field and provides insight on the trends, prospects and challenges of translating this technology to clinical application. Carriers of diverse material compositions are presented, with special focus on the surface properties and emphasis on the similarities and inconsistencies among in vivo experimental paradigms. Research attention is scattered among various nanoparticle DDS and various routes of drug administration, which expresses the lack of consistency among studies. Analysis of current literature reveals lipid-and polymer-based DDS as forerunners of DDS for stroke; however, cell membrane-derived vesicles (CMVs) possess the competitive edge due to their innate biocompatibility and superior efficacy. Conversely, inorganic and carbonbased DDS offer different functionalities as well as varied capacity for loading but suffer mainly from poor safety and general lack of investigation in this area. This review supports the existing literature by systematizing presently available data and accounting for the differences in drugs of choice, carrier types, animal models, intervention strategies and outcome parameters.

show abstract

“…Due to their low stability in biologically relevant media, the fast RES clearance, and the noncontrolled biodistribution, inorganic nanoparticles need to be encapsulated or coated with biomaterials that counteract these limitations. The most common materials used at this aim are polymers, lipids, silica, proteins, and cells …”

Section: Therapy and Diagnosismentioning

confidence: 99%

“…Encapsulation of SPIONs along with the nerve growth factor (NGF) and the mitogen‐activated kinase inhibitor, U0126, inside an apolipoprotein E (ApoE) modified albumin, is another theranostic approach. This system resulted in neurite outgrowth and reduction of the infarct volume, while in parallel noninvasive MRI was used …”

Section: Therapy and Diagnosismentioning

confidence: 99%

“…The use of lipids as a coating material increases the colloidal stability and the systemic circulation both of inorganic nanoparticles and of other therapeutic agents encapsulated inside the matrix. The encapsulation of neuroprotective agents such as citicoline97a or angiogenic factors such as VEGF,97b respectively improves the functional recovery and increases angiogenesis after ischemic stroke. If this therapeutic approach is properly combined with MRI97a or fluoresce and positron emission tomography imaging,97b additional information concerning the effect of the delivered nanotherapeutics in the ischemic tissue can be acquired.…”

Section: Therapy and Diagnosismentioning

confidence: 99%

See 1 more Smart Citation

Advanced Functional Materials and Cell‐Based Therapies for the Treatment of Ischemic Stroke and Postischemic Stroke Effects

Tapeinos

Larrañaga

Tomatis

et al. 2019

Adv Funct Materials

View full text Add to dashboard Cite

Ischemic stroke is considered one of the most threatening neurological disorders with high percentages of mortality and morbidity worldwide. Although in recent years, several nanotechnological advances have improved the survival rates, severe untreated poststroke side‐effects continue to significantly influence the way of life of many. Tissue plasminogen activator and mechanical thrombectomy are considered the gold standards for the treatment of acute cerebral ischemia. These, however, fail to improve postischemic disorders. Herein, after a brief description of the pathophysiology of ischemic stroke and the following biochemical cascade, the most recent biomaterial and cell‐based strategies are reviewed for its treatment. Other therapeutics that have been proposed not only for the treatment of cerebral ischemia but also for the regeneration of the infarcted brain that is responsible for a variety of disorders, including cognitive, motor, and speech problems are also presented. Finally, a few reported studies on diagnostic and theranostic nanostructures are also provided.

show abstract

Stimulating brain recovery after stroke using theranostic albumin nanocarriers loaded with nerve growth factor in combination therapy

Abstract: include embeded figures/tables and also seperate figures/tables Click here to view linked References

Cited by 32 publications

References 51 publications

From Adsorption to Covalent Bonding: Apolipoprotein E Functionalization of Polymeric Nanoparticles for Drug Delivery Across the Blood–Brain Barrier

From Adsorption to Covalent Bonding: Apolipoprotein E Functionalization of Polymeric Nanoparticles for Drug Delivery Across the Blood–Brain Barrier

<p>Nanocarriers for Stroke Therapy: Advances and Obstacles in Translating Animal Studies</p>

Advanced Functional Materials and Cell‐Based Therapies for the Treatment of Ischemic Stroke and Postischemic Stroke Effects

Contact Info

Product

Resources

About